A Comparative Pharmacokinetic Study of a Fixed Dose Combination for Essential Hypertensive Patients: A Randomized Crossover Study in Healthy Human Volunteers

Abstract

Background:

This study was aimed to investigate the relative bioavailability of fixed-dose-combination (FDC) product of amlodipine, telmisartan and hydrochlorothiazide with individual marketed products in healthy male volunteers. Control of blood pressure with fixed dose combination of the above drugs acting through different mechanism have a benefit of convenient dosing in terms of compliance, lower the dose and subsequently reduce the side effects.

Methods:

The authors investigated the relative bioavailability under a fasting state of the 3 drugs in a randomized, open-label, 2-treatment, 2-period, 2-sequence, crossover bioequivalence study with a washout period of 21 days. Plasma concentration of the analytes were assayed in timed samples with a simple, highly sensitive and rapid validated method using HPLC coupled to tandem mass spectrometry that had a lower limit of quantification of 1 ng/mL for all the 3 components.

Results:

Test and reference formulations gave a mean C_max of 5.234±0.914 ng/mL and 4.991±0.563 ng/mL, 108.839±13.601 ng/mL and 114.783±12.315 ng/mL and 97.814±10.779 ng/mL and 93.731±10.018 ng/mL for amlodipine, telmisartan and hydrochlorothiazide respectively. The AUC_0-t of amlodipine, telmisartan and hydrochlorothiazide was 161.484 ng.h/mL, 1 917.644 ng.h/mL and 822.847 ng.h/mL for test formulation and 162.108 ng.h/mL, 2 014.764 ng.h/mL and 829.323 ng.h/mL for reference in the fasting state.

Conclusion:

The 90% confidence intervals for the test/reference ratio of the pharmacokinetic parameters in fasting state (mean C_max, AUC_0-t, and AUC_0-∞) were within the acceptable range of 80.00–125.00. Thus, these findings clearly indicate that the FDC product is bioequivalent with the individual marketed products in terms of rate and extent of drug absorption and is well tolerated with no significant adverse reactions.

Key words

hypertension - bioavailability - amlodipine - telmisartan - hydrochlorothiazide - pharmacokinetics

• References

• 1 Manjula Devi AS, Sriram S, Rajalingam B et al. Evaluation of the Rationality of Fixed Dose Combinations of Cardiovascular drugs in a Multispecialty Tertiary care hospital in Coimbatore, Tamilnadu, India. Hygeia J D Med 2012; 4: 51-58
• 2 Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252
• 3 ESH/ESC Hypertension Guidelines Committee . Practic guidelines for primary care physicians: 2003 ESH/ESC Hypertension Guidelines. J Hypertens 2003; 21: 1779-1786
• 4 Maladkar M, Verma VK, Narsikar KA et al. Triple drug combination of telmisartan, amlodipine and hydrochlorothiazide in the treatment of essential hypertension. Open Journal of Internal Medicine 2012; 2: 67-71
• 5 Waeber B. Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretic in hypertension. Expert Rev Cardiovasc Ther 2003; 1: 43-50
• 6 Kalra S, Kalra B, Agrawal N. Combination therapy in hypertension: An update. Diabetology & Metabolic Syndrome 2010; 2: 44
• 7 Center for Drug Evaluation and Research Pharmacology/Toxicology NDA review and evaluation; 2009. Available from: URL http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200175Orig1s000PharmR.pdf Accessed on 21^st August 2012
• 8 Plosker GL, White WB. Telmisartan/Hydro chlorothiazide: A review of its use as fixed-dose combinations in essential hypertension. Drugs 2008; 68: 1877-1899
• 9 Lacourcière Y, Neutel JM, Schumacher H. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials. Clin Ther 2005; 27: 1795-1805
• 10 Venkata Ram SC. Antihypertensive Efficacy of Angiotensin Receptor Blockers in Combination with Hydrochlorothiazide: A Review of the Factorial-Design Studies. The Journal of Clinical Hypertension 2004; 6: 569-577
• 11 Osvaldo K, Wille O, Decio N et al. The “LOTHAR” Study: Evaluation of efficacy and tolerability of the fixed combination of amlodipine and losartan in the treatment of essential hypertension. Arq Bras Cardiol 2006; 86: 1
• 12 Oparil S, Melino M, Lee J et al. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multi-center, randomized, double-blind, 12-week, parallel-group study. Clin Ther 2010; 32: 1252-1269
• 13 Ram CV, Sachson R, Littlejohn T et al. Management of hypertension in patients with diabetes using an amlodipine, olmesartan medoxomil, and hydrochlorothiazide-based titration regimen. Am J Cardiol 2011; 107: 1346-1352
• 14 WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects. 59^th WMA General Assembly, Seoul, October 2008. Available from: URL http://www.wma.net/en/30publications/10policies/b3/17c.pdf Accessed on 21^st August 2012
• 15 Central Drugs Standard Control Organization, Ministry of Health and Family welfare, Government of India. Guidelines for Bioavailability and Bioequivalence. March 2005. Available from: URL http://cdsco.nic.in/html/be%20guidelines%20draft%20ver10%20march%2016,%2005.pdf Accessed on 21^st August 2012
• 16 Ethical Guidelines for Biomedical Research on Human Participants, Indian Council of Medical Research. ICMR Guidelines 2006; New Delhi 1-111; Available from: URL http:// www.icmr.nic.in/ethical_guidelines.pdf Accessed on 21^st August 2012
• 17 Highlights of Prescribing Information. Available from http://www.accessdata.fda.gov/-drugsatfda_docs/label/2011/019787s052lbl.pdf http://www.accessdata.fda.gov/drugsat-fda_docs/appletter/2012/020850s031ltr.pdf http://www.accessdata.fda.gov/drugsatfda_docs-/label/2011/020504s018lbl.pdf Accessed on 21^st August 2012
• 18 Nation RL, Sansom LN. Bioequivalence requirements for generic products. Pharmacol Ther 1994; 62: 41-55
• 19 FDA. Bioanalytical method validation. Food and drug administration. Guidance for Industry 2001: 1-22. Available from: URL http://www.fda.gov/downloads/Drugs/Guidance-ComplianceRegulatoryInformation/Guidances/UCM070107.pdf Accessed on 19^th November 2011
• 20 Guidance for Industry, Bioavailability and Bioequivalence Studies for Orally Administered Drug Products — General Considerations. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2003. Available from http://www.fda.gov/downloads/Drugs/…/Guidances/ucm070124.pdf Accessed on 21^st August 2012
• 21 EMEA Committee for Medicinal Products for Human Use (CHMP). Guideline on the Investigation of Bioequivalence. London: European Medicines Agency (EMEA) 2008 Available from: URL http://www.ema.europa.eu/docs/en_GB/document_library/-Scientific_guideline/2009/09/WC500003011.pdf